Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04968184




Registration number
NCT04968184
Ethics application status
Date submitted
7/07/2021
Date registered
20/07/2021
Date last updated
13/08/2024

Titles & IDs
Public title
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Scientific title
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD
Secondary ID [1] 0 0
KBP5074-3-001
Universal Trial Number (UTN)
Trial acronym
Clarion-CKD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Diseases 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - KBP-5074

Placebo comparator: Placebo - Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period.

Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period

Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period

Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52.

Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.

Experimental: KBP-5074 - Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period.

Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period

Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period

Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52.

Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.


Treatment: Drugs: Placebo
Participants will orally receive placebo matching to KBP-5074 tablets QD.

Treatment: Drugs: KBP-5074
Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in seated trough cuff SBP from baseline to Week 12
Timepoint [1] 0 0
From baseline to Week 12
Primary outcome [2] 0 0
Change in seated trough cuff SBP from Week 48 to Week 52
Timepoint [2] 0 0
Week 48 to Week 52
Secondary outcome [1] 0 0
Change in seated trough cuff SBP from baseline to Week 24
Timepoint [1] 0 0
From baseline to Week 24
Secondary outcome [2] 0 0
Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12 and Week 24
Timepoint [2] 0 0
From baseline to Week 12 and Week 24
Secondary outcome [3] 0 0
Changes in seated trough cuff SBP and DBP from baseline to Week 48
Timepoint [3] 0 0
From baseline to Week 48
Secondary outcome [4] 0 0
Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 and Week 24 for participants with UACR =30 mg/g at baseline
Timepoint [4] 0 0
From baseline to Week 12 and Week 24
Secondary outcome [5] 0 0
Percentage changes in UACR from baseline to Week 12 and Week 24 for participants with UACR =30 mg/g at baseline
Timepoint [5] 0 0
From baseline to Week 12 and Week 24
Secondary outcome [6] 0 0
Changes in UACR from baseline to Week 12, Week 24, and Week 48
Timepoint [6] 0 0
From baseline to Week 12, Week 24, and Week 48
Secondary outcome [7] 0 0
Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48
Timepoint [7] 0 0
From baseline to Week 12, Week 24, and Week 48
Secondary outcome [8] 0 0
Change in seated trough cuff DBP from Week 48 to Week 52
Timepoint [8] 0 0
Week 48 to Week 52
Secondary outcome [9] 0 0
Change in UACR from Week 48 to Week 52
Timepoint [9] 0 0
Week 48 to Week 52
Secondary outcome [10] 0 0
Percentage change in UACR from Week 48 to Week 52
Timepoint [10] 0 0
Week 48 to Week 52
Secondary outcome [11] 0 0
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Timepoint [11] 0 0
Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination

Eligibility
Key inclusion criteria
* Body mass index (BMI) must be =19 to <45 kg/m^2 at the Screening Visit
* Participant must have uncontrolled hypertension defined as meeting both of the following criteria:

* The participant has a resting seated trough cuff SBP =140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
* The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
* The participant must have Stage 3b (eGFR [EPI] =30 and =44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] =15 and <30 mL/min/1.73 m^2) CKD.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant has a resting seated trough cuff SBP =180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
* Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
* Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
* Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
* Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
* Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
* Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
* Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
* Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
* Participant was administered any other investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/07/2024
Sample size
Target
Accrual to date
Final
652
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Renal Research - Gosford
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Bosnia and Herzegovina
State/province [20] 0 0
Kanton Sarajevo
Country [21] 0 0
Bosnia and Herzegovina
State/province [21] 0 0
Republika Srpska
Country [22] 0 0
Bosnia and Herzegovina
State/province [22] 0 0
Zenicko-dobojski Kanton
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Sofia-Grad
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Gabrovo
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Montana
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Plovdiv
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Ruse
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Sofia
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Stara Zagora
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Varna
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
China
State/province [32] 0 0
Beijing
Country [33] 0 0
China
State/province [33] 0 0
Fujian
Country [34] 0 0
China
State/province [34] 0 0
Guangdong
Country [35] 0 0
China
State/province [35] 0 0
Guangxi
Country [36] 0 0
China
State/province [36] 0 0
Guizhou
Country [37] 0 0
China
State/province [37] 0 0
Hebei
Country [38] 0 0
China
State/province [38] 0 0
Henan
Country [39] 0 0
China
State/province [39] 0 0
Hubei
Country [40] 0 0
China
State/province [40] 0 0
Hunan
Country [41] 0 0
China
State/province [41] 0 0
Jiangsu
Country [42] 0 0
China
State/province [42] 0 0
Nei Mongol (mn)
Country [43] 0 0
China
State/province [43] 0 0
Ningxia
Country [44] 0 0
China
State/province [44] 0 0
Shaanxi
Country [45] 0 0
China
State/province [45] 0 0
Shandong
Country [46] 0 0
China
State/province [46] 0 0
Shanghai
Country [47] 0 0
China
State/province [47] 0 0
Sichuan
Country [48] 0 0
China
State/province [48] 0 0
Zhejiang
Country [49] 0 0
China
State/province [49] 0 0
Chongqing
Country [50] 0 0
China
State/province [50] 0 0
Tianjin
Country [51] 0 0
Croatia
State/province [51] 0 0
Grad Zagreb
Country [52] 0 0
Croatia
State/province [52] 0 0
Osjecko-baranjska Županija
Country [53] 0 0
Croatia
State/province [53] 0 0
Split
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha 4
Country [55] 0 0
Czechia
State/province [55] 0 0
Trebíc
Country [56] 0 0
Czechia
State/province [56] 0 0
Praha 6
Country [57] 0 0
Georgia
State/province [57] 0 0
Ajaria
Country [58] 0 0
Georgia
State/province [58] 0 0
Kvemo Kartli
Country [59] 0 0
Georgia
State/province [59] 0 0
Shida Kartli
Country [60] 0 0
Georgia
State/province [60] 0 0
Batumi
Country [61] 0 0
Georgia
State/province [61] 0 0
Tbilisi
Country [62] 0 0
Germany
State/province [62] 0 0
Baden-Württemberg
Country [63] 0 0
Germany
State/province [63] 0 0
Nordrhein-Westfalen
Country [64] 0 0
Germany
State/province [64] 0 0
Rheinland-Pfalz
Country [65] 0 0
Germany
State/province [65] 0 0
Berlin
Country [66] 0 0
Germany
State/province [66] 0 0
Hannover
Country [67] 0 0
Germany
State/province [67] 0 0
Jena
Country [68] 0 0
Hong Kong
State/province [68] 0 0
Hong Kong
Country [69] 0 0
Hungary
State/province [69] 0 0
Baranya
Country [70] 0 0
Hungary
State/province [70] 0 0
Borsod-Abaúj-Zemplén
Country [71] 0 0
Hungary
State/province [71] 0 0
Csongrád
Country [72] 0 0
Hungary
State/province [72] 0 0
Gyor-Moson-Sopron
Country [73] 0 0
Hungary
State/province [73] 0 0
Heves
Country [74] 0 0
Hungary
State/province [74] 0 0
Pest
Country [75] 0 0
Hungary
State/province [75] 0 0
Veszprém City
Country [76] 0 0
Hungary
State/province [76] 0 0
Budapest
Country [77] 0 0
Hungary
State/province [77] 0 0
Kaposvár
Country [78] 0 0
Israel
State/province [78] 0 0
HaMerkaz
Country [79] 0 0
Israel
State/province [79] 0 0
HaZafon
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Daejeon Gwang'yeogsi [Taejon-Kwangyokshi]
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Gyeonggido [Kyonggi-do]
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
Country [83] 0 0
Latvia
State/province [83] 0 0
Ogres Novads
Country [84] 0 0
Latvia
State/province [84] 0 0
Riga
Country [85] 0 0
Lithuania
State/province [85] 0 0
Kauno Apskritis
Country [86] 0 0
Malaysia
State/province [86] 0 0
Kelantan
Country [87] 0 0
Malaysia
State/province [87] 0 0
Perak
Country [88] 0 0
Malaysia
State/province [88] 0 0
Wilayah Persekutuan Kuala Lumpur
Country [89] 0 0
Poland
State/province [89] 0 0
Kujawsko-pomorskie
Country [90] 0 0
Poland
State/province [90] 0 0
Lódzkie
Country [91] 0 0
Poland
State/province [91] 0 0
Katowice
Country [92] 0 0
Poland
State/province [92] 0 0
Lodz
Country [93] 0 0
Poland
State/province [93] 0 0
Lublin
Country [94] 0 0
Poland
State/province [94] 0 0
Poznan
Country [95] 0 0
Poland
State/province [95] 0 0
Warszawa
Country [96] 0 0
Poland
State/province [96] 0 0
Wroclaw
Country [97] 0 0
Serbia
State/province [97] 0 0
Belgrade
Country [98] 0 0
Serbia
State/province [98] 0 0
Nišavski Okrug
Country [99] 0 0
Serbia
State/province [99] 0 0
Vojvodina
Country [100] 0 0
Serbia
State/province [100] 0 0
Kragujevac
Country [101] 0 0
South Africa
State/province [101] 0 0
Free State
Country [102] 0 0
South Africa
State/province [102] 0 0
Gauteng
Country [103] 0 0
South Africa
State/province [103] 0 0
Kwazulu-Natal
Country [104] 0 0
South Africa
State/province [104] 0 0
Western Cape
Country [105] 0 0
Spain
State/province [105] 0 0
Lugo
Country [106] 0 0
Spain
State/province [106] 0 0
Valenciana, Comunidad
Country [107] 0 0
Spain
State/province [107] 0 0
Barcelona
Country [108] 0 0
Spain
State/province [108] 0 0
Granada
Country [109] 0 0
Spain
State/province [109] 0 0
Madrid
Country [110] 0 0
Spain
State/province [110] 0 0
Valencia
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taichung Municipality
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taipei Special Muncipality
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taichung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taipei
Country [115] 0 0
Taiwan
State/province [115] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
KBP Biosciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[eGFR {EPI}\] =15 to =44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) =140 and \<180 mm Hg and taking 2 or more antihypertensive medications.
Trial website
https://clinicaltrials.gov/study/NCT04968184
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04968184